Versant Ventures related stories
All articles and analysis
NVCF commits $10 mln to Canadian expansion of Versant VenturesNorthleaf Venture Catalyst Fund (NVCF), which in January raised $218 million in its initial close /canada/2014/01/21/first-vcap-fund-of-funds-northleaf-venture-catalyst-fund-nets-218-mln-in-initial-close/ has made a $10 million commitment to U.S. venture capital firm Versant Ventures. NVCF, which is managed by Northleaf Capital Partners, said it wants to back Versant's contribution to Canada's life sciences ecosystem through its specialized model for launching and investing in early-stage companies. Versant has recently established /canada/2014/06/24/versant-ventures-brings-inception-sciences-to-montreal/ incubators in Vancouver, Toronto and Montréal aimed at building companies launched by local academics and entrepreneurs. Other funds backed so far by NVCF include the latest offerings /canada/2014/02/13/nvcf-debuts-with-60-mln-commitments-to-georgian-partners-xpv-capital-funds/ of Canadian firms Georgian Partners and XPV Capital Corp.
Versant Ventures brings Inception Sciences to MontréalU.S. life sciences-focused venture capital firm Versant Ventures has increased its presence in the Canadian market with the launch of a new biopharmaceutical incubator, Inception Sciences Montreal. The launch follows last year's establishment /canada/2013/12/10/versant-ventures-sets-up-shop-in-vancouver-invests-10-mln-series-a-in-inception-4/ by Versant of Blueline Bioscience in Toronto and Inception Sciences Vancouver. The firm said that Inception Sciences Montreal adds a third Canada-based research site to its discovery engine to address the growing appetite of major pharmaceutical companies to enter into innovative venture-backed partnerships.
- Versant Ventures brings Inception Sciences to Montréal
U.S. life sciences-focused venture capital firm Versant Ventures has increased its presence in the Canadian market with the launch of a new biopharmaceutical incubator, Inception Sciences Montreal. The launch follows last year's establishment /canada/2013/12/10/versant-ventures-sets-up-shop-in-vancouver-invests-10-mln-series-a-in-inception-4/ by Versant of Blueline Bioscience in Toronto and Inception Sciences Vancouver. The firm said that Inception Sciences Montreal adds a third Canada-based research site to its discovery engine to address the growing appetite of major pharmaceutical companies to enter into innovative venture-backed partnerships.
Versant Ventures launches Montreal-based biopharmaceutical incubatorVersant Ventures has launched biopharmaceutical incubator Inception Sciences in Montreal. No financial terms were disclosed.
- Versant Ventures launches Montreal-based biopharmaceutical incubator
Versant Ventures has launched biopharmaceutical incubator Inception Sciences in Montreal. No financial terms were disclosed.
Venrock eyes $450 mln for seventh fundVenrock Associates is seeking $450 million for its seventh fund, $100 million more than its previous fund, which closed in 2010.
Venrock marketing Fund VII with $450 mln targetVenrock Associates, one of the oldest venture firms in the business, is back in the market targeting $450 million for its seventh fund, according to two limited partners with knowledge of the fundraising.
- Venrock marketing Fund VII with $450 mln target
Venrock Associates, one of the oldest venture firms in the business, is back in the market targeting $450 million for its seventh fund, according to two limited partners with knowledge of the fundraising.
- VC-backed RuiYi nets $4 mln from Silicon Valley Bank
Sino-American biotech firm RuiYi has received $4 million in debt financing from Silicon Valley Bank. RuiYi's backers include 5AM Ventures, Versant Ventures, Apposite Capital, SR One and Merck Serono Ventures.
- Venrock hires former Versant Ventures exec Samuels as partner
Venrock has hired Camille Samuels and Doug Dooley in the firm's Palo Alto office. Samuels, a former managing director at Versant Ventures, joins as a partner to focus on biotech and consumer health, while expanding her focus into healthcare companies. Dooley, formerly an entrepreneur, will focus on infrastructure technologies and cloud-centric software.